Economic evaluation of next‐generation sequencing techniques in diagnosis of genetic disorders: A systematic review

Abstract

AbstractIn recent years, massively parallel sequencing or next generation sequencing (NGS) has considerably changed both the research and diagnostic fields, and rapid developments have led to the combination of NGS techniques in clinical practice, ease of analysis, and detection of genetic mutations. This article aimed at reviewing the economic evaluation studies of the NGS techniques in the diagnosis of genetic diseases. In this systematic review, scientific databases (PubMed, EMBASE, Web of Science, Cochrane, Scopus, and CEA registry) were searched from 2005 to 2022 to identify the related literature on the economic evaluation of NGS techniques in the diagnosis of genetic diseases. Full‐text reviews and data extraction were all performed by two independent researchers. The quality of all the articles included in this study was evaluated using the Checklist of Quality of Health Economic Studies (QHES). Out of 20 521 screened abstracts, 36 studies met the inclusion criteria. The mean score of the QHES checklist for the studies was 0.78 (high quality). Seventeen studies were conducted based on modeling. Cost‐effectiveness analysis, cost‐utility analysis, and cost‐minimization analysis were done in 26 studies, 13 studies, and 1 study, respectively. Based on the available evidence and findings, exome sequencing, which is one of the NGS techniques, could have the potential to be used as a cost‐effective genomic test to diagnose children with suspected genetic diseases. The results of the present study support the cost‐effectiveness of exome sequencing in diagnosing suspected genetic disorders. However, the use of exome sequencing as a first‐ or second‐line diagnostic test is still controversial. Most studies have been conducted in high‐income countries, and research on the cost‐effectiveness of NGS methods is recommended in low‐ and middle‐income countries.